Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD

Bone Marrow Transplantation

Volumn 42, Issue 11, 2008, Pages 757-760

  Magro, L ^a   Catteau, B ^b   Coiteux, V ^a   Bruno, B ^a   Jouet, J P ^a,b,c   Yakoub Agha, I ^a,b,c  

^a Service des Maladies du Sang   (France)

^b Service de Dermatologie   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EVEROLIMUS; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLATELET DERIVED GROWTH FACTOR; STEROID; THALIDOMIDE; TRANSFORMING GROWTH FACTOR;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LICHENOID; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; SCLERODERMA; TREATMENT FAILURE; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; FEMALE; FIBROBLASTS; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 58149475244     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.252     Document Type: Article

References (28)

1. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
2. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004; 104: 3028-3037.
3. Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105: 3749-3756.
4. Micol JB, Berthon C, Tricot S, Terriou L, Darre S, Cracco P et al. Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: A study of 25 consecutive patients and a literature review. Leuk Lymphoma 2007; 48: 321-329.
5. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963-971.
6. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: A series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30: 287-295.
7. Marcellus DC, Altomonte VL, Farmer ER, Horn TD, Freemer CS, Grant J et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93: 66-70.
8. Skert C, Patriarca F, Sperotto A, Cerno M, Fili C, Zaja F et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: Incidence, predictors and outcome. Haematologica 2006; 91: 258-261.
9. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
10. O'Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003; 40 (2 Suppl 2): 26-30.
11. Blanke C. Current management of GIST. Clin Adv Hematol Oncol 2004; 2: 280-283.
12. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007; 33: 357-373.
13. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
14. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316.
15. Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2006; 347: 31-35.
16. Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: A preclinical study. Dermatology 2008; 216: 109-117.
17. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 130-140.
18. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-4378.
19. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
20. Gay S, Jones Jr RE, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92: 301-303.
21. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999; 96: 12719-12724.
22. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992; 175: 1413-1416.
23. Santiago B, Gutierrez-Canas I, Dotor J, Palao G, Lasarte JJ, Ruiz J et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005; 125: 450-455.
24. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-333.
25. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-322.
26. Kiani A, Habermann I, Schake K, Neubauer A, Rogge L, Ehninger G. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Haematologica 2003; 88: 754-761.
27. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007; 35: 1266-1271.
28. Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: The narrow line between immune tolerance and activation. Trends Mol Med 2005; 11: 397-402.